Cargando…
Adaptive multiarm multistage clinical trials
Two methods for designing adaptive multiarm multistage (MAMS) clinical trials, originating from conceptually different group sequential frameworks are presented, and their operating characteristics are compared. In both methods pairwise comparisons are made, stage‐by‐stage, between each treatment ar...
Autores principales: | Ghosh, Pranab, Liu, Lingyun, Mehta, Cyrus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065228/ https://www.ncbi.nlm.nih.gov/pubmed/32048313 http://dx.doi.org/10.1002/sim.8464 |
Ejemplares similares
-
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
por: Mason, Malcolm D., et al.
Publicado: (2017) -
D‐optimal designs for multiarm trials with dropouts
por: Lee, Kim May, et al.
Publicado: (2019) -
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2016) -
A Multiarmed Bandit Approach to Adaptive Water Quality Management
por: Martin, David M, et al.
Publicado: (2020) -
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2012)